bexagliflozin bexagliflozin bexagliflozin, sold under the brand name brenzavvy, is an antidiabetic medication used to improve glycemic control in adults with type 2 diabetes as an adjunct to diet and exercise. it is a sodium-glucose cotransporter 2 (sglt2) inhibitor that is taken by mouth. bexagliflozinclinical datatrade namesbrenzavvy, bexacatahfs/drugs.commicromedex detailed consumer informationlicense data us dailymed: bexagliflozin routes ofadministrationby mouthatc codenonelegal statuslegal status us: ℞-only identifiers iupac name (2s,3r,4r,5s,6r)-2-methyl]phenyl]-6-(hydroxymethyl)oxane-3,4,5-triol cas number1118567-05-7pubchem cid25195624drugbankdb12236chemspider26609013uniiey00jf42fvkeggd10865chemblchembl1808388chemical and physical dataformulac24h29clo7molar mass464.94 g·mol−13d model (jsmol)interactive image smiles c1cc1occoc2=cc=c(c=c2)cc3=c(c=cc(=c3)4((((o4)co)o)o)o)cl inchi inchi=1s/c24h29clo7/c25-19-8-3-15(24-23(29)22(28)21(27)20(13-26)32-24)12-16(19)11-14-1-4-17(5-2-14)30-9-10-31-18-6-7-18/h1-5,8,12,18,20-24,26-29h,6-7,9-11,13h2/t20-,21-,22+,23-,24+/m1/s1key:btcrkokvytvolu-sjsrkzjxsa-n medical uses bexagliflozin is indicated to improve glycemic control in adults with type 2 diabetes as an adjunct to diet and exercise. research a 96-week phase 2 clinical study of adults with type 2 diabetes showed that bexagliflozin monotherapy provided a durable, clinically meaningful improvement of glycemic control, with a substantial reduction in weight and blood pressure, but no increase in the rate of significant adverse events. in a clinical study of patients with type 2 diabetes and stage 3a/3b chronic kidney disease, bexagliflozin was well tolerated and shown to reduce hemoglobin a1c levels, body weight, systolic blood pressure and albuminuria. veterinary uses the data from two six-month field studies and an extended use field study demonstrated that bexagliflozin was over 80% effective in improving glycemic control in cats with diabetes mellitus. bexagliflozin, sold under the brand name bexacat, is an antidiabetic medication used to improve glycemic control in cats with diabetes. bexacat is the first sodium-glucose cotransporter 2 (sglt2) inhibitor new animal drug approved by the us food and drug administration (fda) in any animal species. it was approved for medical use in the united states in december 2022. bexacat is sponsored by increvet inc., based in boston, massachusetts. elanco licensed development and commercialization rights for bexagliflozin from bexcafe, an affiliate of increvet.